Evidence map›Paper›PMID 26978735›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2016

Potential Diagnostic and Prognostic Value of Plasma Circulating MicroRNA-182 in Human Glioma.

Yilei Xiao, Lina Zhang, Zikun Song, Chuanjun Guo, Jianxin Zhu, Zhongmin Li, Shugan Zhu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 7 pooled it
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 7 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Liquid biomarkers in glioma.Brain tumor pathology · 2023
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yilei XiaoDepartment of Neurosurgery, Qilu Hospital of Shandong University, Jinan, Shandong, China (mainland).
Lina ZhangDepartment of Intensive Care Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China (mainland).
Zikun SongDepartment of Intensive Care Medicine, The People's Second Hospital of Liaocheng, Linqing, Shandong, China (mainland).
Chuanjun GuoDepartment of Neurosurgery, Liaocheng People's Hospital, Liaocheng, Shandong, China (mainland).
Jianxin ZhuDepartment of Neurosurgery, Liaocheng People's Hospital, Liaocheng, Shandong, China (mainland).
Zhongmin LiDepartment of Neurosurgery, Liaocheng People's Hospital, Liaocheng, Shandong, China (mainland).
Shugan ZhuDepartment of Neurosurgery, Qilu Hospital of Shandong University, Jinan, Shandong, China (mainland).
Liaocheng People's Hospital · CNQilu Hospital of Shandong University · CNPeople’s Hospital of Linqing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies showed the aberrant expression of microRNA-182 (miR-182) in glioma tissue. However, the exact role of circulating miR-182 in glioma remains unclear. Here, we confirmed the expression of plasma circulating miR-182 in glioma patients, and further explored its potential diagnostic and prognostic value. MATERIAL/

methodsReal-time quantitative PCR (RT-PCR) was used to measure circulating cell-free miR-182 from 112 glioma patients and 54 healthy controls.

resultsOur findings showed that the level of circulating miR-182 in glioma patients was higher than that in healthy controls (P<0.001), which was significantly associated with KPS score (P=0.025) and WHO grade (P<0.001). The area under the receiver operating characteristic (ROC) curve (AUC) was 0.778. The optimal cut-off value was 1.56, and the sensitivity and specificity were 58.5% and 85.2%, respectively. Interestingly, a high predictive value of circulating miR-182 was observed in high-grade glioma (AUC=0.815). However, the AUC was lower in low-grade glioma (AUC=0.621). Kaplan-Meier analysis demonstrated that the cumulative 5-year overall survival rate in the high miR-182 group was significantly lower than that in the low miR-182 group in both overall survival (OS) (P=0.003) and disease-free survival (DFS) (P=0.006). Moreover, multivariate Cox analysis revealed that circulating miR-182 was an independent prognostic indicator for OS (P=0.034) and DFS (P=0.013).

conclusionsThese results suggest that circulating miR-182 may be a potential noninvasive biomarker for the diagnosis and prognosis of human glioma.

Indexed as

Brain NeoplasmsCase-Control StudiesDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticGliomaHumansKaplan-Meier EstimateMaleMicroRNAsMiddle AgedMultivariate AnalysisPrognosisROC CurveMicroRNAsMirn182 microRNA, human

Identifiers

PMID26978735
PMCPMC4795091
OpenAlexW2302492670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.